Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06579352 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of UC-MSC in DMD Patients

StatusActive, Not Recruiting
PhasePhase 2
Started2024-08-05
View on ClinicalTrials.gov ↗
The primary objective of this study is to provide UC-MSC treatment to patients with DMD. Secondary objectives will be to further evaluate treatment-related adverse events as well as changes in DMD-related functional testing/assessments, blood laboratories, and inflammation related biomarker levels over time.

Amendment record

Amended 3 times since 2024-08-27; most recent filed 2026-08-12. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-12
Amendment Study Identification, Study Status v3
2026-07-22
Amendment Study Status v2
2026-07-17
Amendment Available→Active, Not Recruiting Study Identification, Study Status, Oversight, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations, IPDSharing v1
2024-08-27
Original filing
Trial Details
NCT Number NCT06579352
Lead Sponsor MED Institute Inc.
Collaborators: Signature Biologics
Conditions Duchenne Muscular Dystrophy
Enrollment 35 participants
Start Date 2024-08-05
Primary Completion 2028-10-31 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14